Related Experiment Video
Updated: Jun 20, 2026
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell carcinoma
Valentina Zuco1, Rosanna Supino, Enrica Favini
1Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy.
Abstract:
ST1968 (namitecan), a novel 7-modified hydrophilic camptothecin, was found to be effective against tumor models relatively resistant to topotecan and irinotecan. Based on this observation, this study was designed to investigate the cellular and antitumor effects of ST1968 in a subline of A431, squamous cell carcinoma, selected for resistance to topotecan (A431/TPT). This model was characterized by a slow growth rate, associated with downregulation of EGFR and topoisomerase I. In contrast to other camptothecins (SN38 and gimatecan), ST1968 was able to overcome almost completely the resistance at cellular level. The cellular pharmacokinetics indicated a comparable accumulation and retention of ST1968 in sensitive and resistant cells, in spite of expression of the efflux transporter, P-glycoprotein, in resistant cells. The uptake and retention of topotecan were dramatically reduced in both tumor cell lines, but more evident in the resistant one. In contrast to topotecan, ST1968 retained an outstanding efficacy in vivo against the resistant tumor (A431/TPT). The results are consistent with the interpretation that ST1968 was able to overcome the most relevant mechanisms associated with the development of topotecan resistance (i.e., slow proliferation and target downregulation) owing to its peculiar pharmacokinetic behaviour.
Insights
Namitecan (ST1968) effectively overcomes resistance to topotecan in squamous cell carcinoma models. Its unique pharmacokinetics allow it to bypass common resistance mechanisms, showing significant efficacy where other drugs fail.
Area of Science:
- Oncology
- Pharmacology
- Cancer Biology
Background:
- Squamous cell carcinoma models can develop resistance to topoisomerase I inhibitors like topotecan.
- Mechanisms of resistance include slow proliferation, EGFR downregulation, and topoisomerase I target downregulation.
Purpose of the Study:
- To investigate the efficacy of ST1968 (namitecan) in a topotecan-resistant A431 squamous cell carcinoma subline (A431/TPT).
- To elucidate the cellular and antitumor effects of ST1968 in overcoming topotecan resistance.
Main Methods:
- Development of a topotecan-resistant A431/TPT cell line.
- Characterization of the resistant model for growth rate, EGFR, topoisomerase I, and P-glycoprotein expression.
- In vitro cellular accumulation, retention, and cytotoxicity assays for ST1968 and topotecan.
- In vivo antitumor efficacy studies of ST1968 in the resistant tumor model.
Main Results:
- ST1968 demonstrated significant cellular efficacy against A431/TPT cells, overcoming resistance seen with other camptothecins.
- Cellular pharmacokinetics showed comparable ST1968 accumulation and retention in sensitive and resistant cells, despite P-glycoprotein expression.
- Topotecan uptake and retention were significantly reduced in resistant cells.
- ST1968 exhibited outstanding in vivo efficacy against the resistant A431/TPT tumor.
Conclusions:
- ST1968 effectively overcomes key mechanisms of topotecan resistance, including slow proliferation and target downregulation.
- The unique pharmacokinetic profile of ST1968 is crucial for its ability to bypass resistance.
- ST1968 represents a promising therapeutic agent for resistant squamous cell carcinoma.
More Related Videos
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
08:19Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
